Anti-CD20 monoclonal antibodies: reviewing a revolution

被引：66
作者：
Casan, J. M. L. [1 ]
Wong, J. [1 ]
Northcott, M. J. [2 ,3 ]
Opat, S. [1 ,3 ]
机构：
[1] Monash Hlth, Haematol Dept, Melbourne, Vic, Australia
[2] Monash Hlth, Rheumatol Dept, Melbourne, Vic, Australia
[3] Monash Univ, Sch Clin Sci, Melbourne, Vic, Australia
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2018年 / 14卷 / 12期
关键词：
Monoclonal antibody; CD20; rituximab; obinutuzumab; immunotherapy; lymphoma; CHRONIC LYMPHOCYTIC-LEUKEMIA; B-CELL LYMPHOMA; MULTICENTER PHASE-II; NON-HODGKIN-LYMPHOMA; PREVIOUSLY UNTREATED PATIENTS; ACTIVE RHEUMATOID-ARTHRITIS; REFRACTORY FOLLICULAR LYMPHOMA; RITUXIMAB MAINTENANCE IMPROVES; SYSTEMIC-LUPUS-ERYTHEMATOSUS; CHEMOTHERAPY PLUS RITUXIMAB;
D O I：
10.1080/21645515.2018.1508624
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have revolutionised the treatment of B cell hematological malignancies and have become a cornerstone of modern gold-standard practice. Additionally, the potent efficacy of these agents in depleting the B cell compartment has been used in the management of a broad array of autoimmune diseases. Multiple iterations of these agents have been investigated and are routinely used in clinical practice. In this review, we will discuss the physiology of CD20 and its attractiveness as a therapeutic target, as well as the pharmacology, pre-clinical and clinical data for the major anti-CD20 monoclonal antibodies: rituximab, obinutuzumab and ofatumumab.
引用
收藏
页码：2820 / 2841
页数：22
相关论文
共 212 条
  • [1] Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response
    Abes, Riad
    Gelize, Emmanuelle
    Fridman, Wolf Herman
    Teillaud, Jean-Luc
    [J]. BLOOD, 2010, 116 (06) : 926 - 934
  • [2] [Anonymous], LEUKEMIA
  • [3] [Anonymous], J CLIN ONCOL
  • [4] [Anonymous], MULT SCLER
  • [5] [Anonymous], 2018, OVERALL SURVIVAL BEN
  • [6] [Anonymous], 2014, FOR IMMUNOPATHOL DIS, DOI DOI 10.1615/FORUMIMMUNDISTHER.2015014073
  • [7] [Anonymous], B CELL TROPHIC FACTO
  • [8] Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial
    Assouline, Sarit
    Buccheri, Valeria
    Delmer, Alain
    Gaidano, Gianluca
    Trneny, Marek
    Berthillon, Natalia
    Brewster, Michael
    Catalani, Olivier
    Li, Sai
    McIntyre, Christine
    Sayyed, Pakeeza
    Badoux, Xavier
    [J]. LANCET HAEMATOLOGY, 2016, 3 (03): : E128 - E138
  • [9] Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma
    Bachy, Emmanuel
    Houot, Roch
    Morschhauser, Franck
    Sonet, Anne
    Brice, Pauline
    Belhadj, Karim
    Cartron, Guillaume
    Audhuy, Bruno
    Ferme, Christophe
    Feugier, Pierre
    Sebban, Catherine
    Delwail, Vincent
    Maisonneuve, Herve
    Le Gouill, Steven
    Lefort, Sophie
    Brousse, Nicole
    Foussard, Charles
    Salles, Gilles
    [J]. HAEMATOLOGICA, 2013, 98 (07) : 1107 - 1114
  • [10] Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
    Beers, Stephen A.
    French, Ruth R.
    Chan, H. T. Claude
    Lim, Sean H.
    Jarrett, Timothy C.
    Vidal, Regina Mora
    Wijayaweera, Sahan S.
    Dixon, Sandra V.
    Kim, Hyungjin
    Cox, Kerry L.
    Kerr, Jonathan P.
    Johnston, David A.
    Johnson, Peter W. M.
    Verbeek, J. Sjef
    Glennie, Martin J.
    Cragg, Mark S.
    [J]. BLOOD, 2010, 115 (25) : 5191 - 5201
12345678910